Cargando…

Targeted Assessment of the EGFR Status as Reflex Testing in Treatment-Naive Non-Squamous Cell Lung Carcinoma Patients: A Single Laboratory Experience (LPCE, Nice, France)

Background: Assessment of actionable EGFR mutations is mandatory for treatment-naïve advanced or metastatic non-squamous lung carcinoma (NSLC), but the results need to be obtained in less than 10 working days. For rapid EGFR testing, an EGFR-specific polymerase chain reaction (PCR) assay is an alter...

Descripción completa

Detalles Bibliográficos
Autores principales: Lassalle, Sandra, Hofman, Véronique, Heeke, Simon, Benzaquen, Jonathan, Long, Elodie, Poudenx, Michel, Lantéri, Elisabeth, Boutros, Jacques, Tanga, Virginie, Zahaf, Katia, Lalvée, Salomé, Lespinet, Virginie, Bordone, Olivier, Félix, Jean-Marc, Bonnetaud, Christelle, Marquette, Charles, Ilie, Marius, Hofman, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225982/
https://www.ncbi.nlm.nih.gov/pubmed/32294880
http://dx.doi.org/10.3390/cancers12040955
_version_ 1783534180331683840
author Lassalle, Sandra
Hofman, Véronique
Heeke, Simon
Benzaquen, Jonathan
Long, Elodie
Poudenx, Michel
Lantéri, Elisabeth
Boutros, Jacques
Tanga, Virginie
Zahaf, Katia
Lalvée, Salomé
Lespinet, Virginie
Bordone, Olivier
Félix, Jean-Marc
Bonnetaud, Christelle
Marquette, Charles
Ilie, Marius
Hofman, Paul
author_facet Lassalle, Sandra
Hofman, Véronique
Heeke, Simon
Benzaquen, Jonathan
Long, Elodie
Poudenx, Michel
Lantéri, Elisabeth
Boutros, Jacques
Tanga, Virginie
Zahaf, Katia
Lalvée, Salomé
Lespinet, Virginie
Bordone, Olivier
Félix, Jean-Marc
Bonnetaud, Christelle
Marquette, Charles
Ilie, Marius
Hofman, Paul
author_sort Lassalle, Sandra
collection PubMed
description Background: Assessment of actionable EGFR mutations is mandatory for treatment-naïve advanced or metastatic non-squamous lung carcinoma (NSLC), but the results need to be obtained in less than 10 working days. For rapid EGFR testing, an EGFR-specific polymerase chain reaction (PCR) assay is an alternative and simple approach compared to next generation sequencing (NGS). Here, we describe how a rapid EGFR-specific PCR assay can be implemented in a single laboratory center (LPCE, Nice, France) as reflex testing in treatment-naïve NSLC. Methods: A total of 901 biopsies from NSLC with more than 10% of tumor cells were prospectively and consecutively evaluated for EGFR mutation status between November 2017 and December 2019 using the Idylla system (Biocartis NV, Mechelen, Belgium). NGS was performed for nonsmokers with NSLC wild type for EGFR, ALK, ROS1, and BRAF and with less than 50% PD-L1 positive cells using the Hotspot panel (Thermo Fisher Scientific, Waltham, MA, USA). Results: Results were obtained from 889/901 (97%) biopsies with detection of EGFR mutations in 114/889 (13%) cases using the Idylla system. Among the 562 EGFR wild type tumors identified with Idylla, NGS detected one actionable and one nonactionable EGFR mutation. Conclusions: Rapid and targeted assessment of EGFR mutations in treatment-naïve NSLC can be implemented in routine clinical practice. However, it is mandatory to integrate this approach into a molecular algorithm that allows evaluation of potentially actionable genomic alterations other than EGFR mutations.
format Online
Article
Text
id pubmed-7225982
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72259822020-05-18 Targeted Assessment of the EGFR Status as Reflex Testing in Treatment-Naive Non-Squamous Cell Lung Carcinoma Patients: A Single Laboratory Experience (LPCE, Nice, France) Lassalle, Sandra Hofman, Véronique Heeke, Simon Benzaquen, Jonathan Long, Elodie Poudenx, Michel Lantéri, Elisabeth Boutros, Jacques Tanga, Virginie Zahaf, Katia Lalvée, Salomé Lespinet, Virginie Bordone, Olivier Félix, Jean-Marc Bonnetaud, Christelle Marquette, Charles Ilie, Marius Hofman, Paul Cancers (Basel) Article Background: Assessment of actionable EGFR mutations is mandatory for treatment-naïve advanced or metastatic non-squamous lung carcinoma (NSLC), but the results need to be obtained in less than 10 working days. For rapid EGFR testing, an EGFR-specific polymerase chain reaction (PCR) assay is an alternative and simple approach compared to next generation sequencing (NGS). Here, we describe how a rapid EGFR-specific PCR assay can be implemented in a single laboratory center (LPCE, Nice, France) as reflex testing in treatment-naïve NSLC. Methods: A total of 901 biopsies from NSLC with more than 10% of tumor cells were prospectively and consecutively evaluated for EGFR mutation status between November 2017 and December 2019 using the Idylla system (Biocartis NV, Mechelen, Belgium). NGS was performed for nonsmokers with NSLC wild type for EGFR, ALK, ROS1, and BRAF and with less than 50% PD-L1 positive cells using the Hotspot panel (Thermo Fisher Scientific, Waltham, MA, USA). Results: Results were obtained from 889/901 (97%) biopsies with detection of EGFR mutations in 114/889 (13%) cases using the Idylla system. Among the 562 EGFR wild type tumors identified with Idylla, NGS detected one actionable and one nonactionable EGFR mutation. Conclusions: Rapid and targeted assessment of EGFR mutations in treatment-naïve NSLC can be implemented in routine clinical practice. However, it is mandatory to integrate this approach into a molecular algorithm that allows evaluation of potentially actionable genomic alterations other than EGFR mutations. MDPI 2020-04-13 /pmc/articles/PMC7225982/ /pubmed/32294880 http://dx.doi.org/10.3390/cancers12040955 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lassalle, Sandra
Hofman, Véronique
Heeke, Simon
Benzaquen, Jonathan
Long, Elodie
Poudenx, Michel
Lantéri, Elisabeth
Boutros, Jacques
Tanga, Virginie
Zahaf, Katia
Lalvée, Salomé
Lespinet, Virginie
Bordone, Olivier
Félix, Jean-Marc
Bonnetaud, Christelle
Marquette, Charles
Ilie, Marius
Hofman, Paul
Targeted Assessment of the EGFR Status as Reflex Testing in Treatment-Naive Non-Squamous Cell Lung Carcinoma Patients: A Single Laboratory Experience (LPCE, Nice, France)
title Targeted Assessment of the EGFR Status as Reflex Testing in Treatment-Naive Non-Squamous Cell Lung Carcinoma Patients: A Single Laboratory Experience (LPCE, Nice, France)
title_full Targeted Assessment of the EGFR Status as Reflex Testing in Treatment-Naive Non-Squamous Cell Lung Carcinoma Patients: A Single Laboratory Experience (LPCE, Nice, France)
title_fullStr Targeted Assessment of the EGFR Status as Reflex Testing in Treatment-Naive Non-Squamous Cell Lung Carcinoma Patients: A Single Laboratory Experience (LPCE, Nice, France)
title_full_unstemmed Targeted Assessment of the EGFR Status as Reflex Testing in Treatment-Naive Non-Squamous Cell Lung Carcinoma Patients: A Single Laboratory Experience (LPCE, Nice, France)
title_short Targeted Assessment of the EGFR Status as Reflex Testing in Treatment-Naive Non-Squamous Cell Lung Carcinoma Patients: A Single Laboratory Experience (LPCE, Nice, France)
title_sort targeted assessment of the egfr status as reflex testing in treatment-naive non-squamous cell lung carcinoma patients: a single laboratory experience (lpce, nice, france)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225982/
https://www.ncbi.nlm.nih.gov/pubmed/32294880
http://dx.doi.org/10.3390/cancers12040955
work_keys_str_mv AT lassallesandra targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance
AT hofmanveronique targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance
AT heekesimon targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance
AT benzaquenjonathan targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance
AT longelodie targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance
AT poudenxmichel targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance
AT lanterielisabeth targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance
AT boutrosjacques targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance
AT tangavirginie targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance
AT zahafkatia targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance
AT lalveesalome targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance
AT lespinetvirginie targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance
AT bordoneolivier targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance
AT felixjeanmarc targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance
AT bonnetaudchristelle targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance
AT marquettecharles targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance
AT iliemarius targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance
AT hofmanpaul targetedassessmentoftheegfrstatusasreflextestingintreatmentnaivenonsquamouscelllungcarcinomapatientsasinglelaboratoryexperiencelpcenicefrance